header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

OSTEOSARCOMA IN PAGET’S DISEASE OF BONE: A RETROSPECTIVE ANALYSIS OF THE RIZZOLI INSTITUTE EXPERIENCE.



Abstract

Purpose: Aim of this study was to analyse our Institution experience with osteosarcoma in Paget’s disease (PD).

Methods: Twenty-six patients treated between 1961 and 2006 were retrospectively analysed. Information focusing on treatment, imaging and oncologic outcome were obtained from clinical charts.

Results Fifteen patients had previous diagnosis (mean time 9 yrs) of monostotic (80%) or polyostotic (20%) PD; in 11 sarcoma and PD were contemporarily diagnosed. The most frequents osteosarcoma histotypes observed were osteoblastic in 18 cases (69%), fibroblastic in 5 cases (19%), teleangectasic in 2 patients and chondroblastic in one case. In 6 patients surgery only was performed: 3 amputations and 3 resections. In 3 pts surgery (amputation), adjuvant chemotherapy and radio-therapy were given. In 1 pt surgery (amputation) and radiotherapy. In 12 patients surgery and chemotherapy: adjuvant in 10 cases (8 amputations and 2 resections) and neoadjuvant in 2 (both amputations). Two patients had only radiotherapy and 2 had only chemotherapy. Oncologic outcome showed 4 pts with no evidence sisease at a mean follow up of 139 months (min.42.6, max.257.4) and 22 died with disease at a mean time of 20.15 months (min.1, max. 84). One patient only of 6 (11%) treated with surgery only is NED at 10 years, while the other 5 died from disease at a mean time of 30 mos. Three of 12 patients (25%) treated with surgery and chemotherapy are NED at a mean follow up of 12 years, while 9 died of disease at a mean time of 24 months. All patients treated without surgery died at of 7.5 mos on average (min.1 – max.13.7).

Conclusions: Sarcomas in PD have a poor prognosis in pts treated without surgery or with surgery only. Surgery with chemotherapy – when feasible – improves prognosis.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Tel: +41 44 448 44 00; Email: office@efort.org

Author: Pietro Ruggieri, Italy

E-mail: pietro.ruggieri@ior.it